Eli Lilly (LLY)

930.35
-58.77 (-5.94%)
NYSE · Last Trade: Mar 17th, 8:30 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Movefool.com
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Via The Motley Fool · March 17, 2026
Stock Market Today, March 17: Markets Edge Upwards as Fed Meeting Opensfool.com
Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.
Via The Motley Fool · March 17, 2026
Why Eli Lilly (LLY) Shares Are Plunging Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...
Via StockStory · March 17, 2026
Worried the AI Hype Won't Last? These Dividend Stocks Offer Safer Exposurefool.com
You don't have to go all in to profit from AI.
Via The Motley Fool · March 17, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · March 17, 2026
LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloffstocktwits.com
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.
Via Stocktwits · March 17, 2026
Why Eli Lilly Stock Just Droppedfool.com
Eli Lilly's stock price is based on growth rates that might fall short.
Via The Motley Fool · March 17, 2026
Tuesday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
Eli Lilly Analyst Flags Overhyped Obesity Drug Expectationsbenzinga.com
HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.
Via Benzinga · March 17, 2026
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stockfool.com
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Via The Motley Fool · March 17, 2026
Tuesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
Should You Avoid Pfizer? Here's the Key Risk to Watchfool.com
Pfizer has reached a turning point.
Via The Motley Fool · March 17, 2026
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?fool.com
Eli Lilly's stock is down this year, and its high valuation may be a big reason why.
Via The Motley Fool · March 16, 2026
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per
Via MarketMinute · March 16, 2026
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocksfool.com
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Via The Motley Fool · March 16, 2026
3 Companies at the Forefront of the GLP-1 Pill Warsmarketbeat.com
Via MarketBeat · March 16, 2026
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trialbenzinga.com
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.
Via Benzinga · March 16, 2026
3 Quality Compounders to Own for Decades
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...
Via StockStory · March 16, 2026
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Sharesfool.com
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.
Via The Motley Fool · March 15, 2026
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Sharefool.com
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.
Via The Motley Fool · March 15, 2026
3 Stocks That Could Be Next to Announce a Stock Splitmarketbeat.com
Via MarketBeat · March 15, 2026
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demandmarketbeat.com
Via MarketBeat · March 15, 2026
Is Eli Lilly's Weight Loss Empire in Trouble?fool.com
It won't be easy to knock the company off its pedestal.
Via The Motley Fool · March 13, 2026
The Great Rotation: Investors Retreat to Defensive Fortresses as 2026 Market Volatility Bites
As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and South America, coupled with a domestic crisis of confidence in central bank leadership, has sent major indices
Via MarketMinute · March 13, 2026
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in favor of battle-tested stalwarts. On Friday, March 13, 2026, JPMorgan Chase & Co. (NYSE: JPM) and Eli Lilly and
Via MarketMinute · March 13, 2026